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density after IFN-α immune challenge in healthy
human volunteers
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Abstract
Depression is associated with peripheral inflammation, but its link with brain microglial activity remains unclear. In
seven healthy males, we used repeated translocator protein-Positron Emission Tomography (TSPO-PET) dynamic scans
with [11C]PBR28 to image brain microglial activation before and 24 h after the immune challenge interferon (IFN)-α. We
also investigated the association between changes in peripheral inflammation, changes in microglial activity, and
changes in mood. IFN-α administration decreased [11C]PBR28 PET tissue volume of distribution (Vt) across the brain
(−20 ± 4%; t6= 4.1, p= 0.01), but after correction for radioligand free-plasma fraction there were no longer any
changes (+23 ± 31%; t= 0.1, p= 0.91). IFN-α increased serum IL-6 (1826 ± 513%, t6=−7.5, p < 0.001), IL-7 (39 ± 12%,
t6=−3.6, p= 0.01), IL-10 (328 ± 48%, t6=−12.8, p < 0.001), and IFN-γ (272 ± 64%, t6=−7.0, p < 0.001) at 4–6 h, and
increased serum TNF-α (49 ± 7.6%, t6=−7.5, p < 0.001), IL-8 (39 ± 12%, t6=−3.5, p= 0.013), and C-reactive protein
(1320 ± 459%, t6=−7.2, p < 0.001) at 24 h. IFN-α induced temporary mood changes and sickness symptoms after
4–6 h, measured as an increase in POMS-2 total mood score, confusion and fatigue, and a decrease in vigor and
friendliness (all p ≤ 0.04). No association was found between changes in peripheral inflammation and changes in PET
or mood measures. Our work suggests that brain TSPO-PET signal is highly dependent of inflammation-induced
changes in ligand binding to plasma proteins. This limits its usefulness as a sensitive marker of neuroinflammation and
consequently, data interpretation. Thus, our results can be interpreted as showing either that [11C]PBR28 is not
sensitive enough under these conditions, or that there is simply no microglial activation in this model.
Introduction
Microglial activation has been proposed as the core
neuroinflammatory process in psychiatric disorders.
Microglia are brain resident macrophages and the primary
immune effector cells in the central nervous system.
Previous preclinical and postmortem studies investigating
the role of inflammation in depression have shown an
association between depressive symptoms and greater
microglial activity1–4, suggesting that the brain’s innate
immune response might play a role in the pathophysiol-
ogy of depression. In vivo, microglial activation can be
measured with positron emission tomography (PET)
radioligands targeting translocator protein (TSPO), a
protein located on outer mitochondrial membranes in
microglia, as TSPO appears to be overexpressed when
microglial cells are activated during neuroinflammation5.
Despite some negative results6, the majority of TSPO-
PET studies in patients with depression have reported
increased TSPO binding compared with healthy con-
trols7–11, suggesting increased microglial activation in
these patients. These studies thus propose that the
inflammatory response in depression involves not only the
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periphery12,13 but also the brain. Indeed, behavioural
symptoms of depression might be induced by peripheral
cytokines and immune cells acting on the brain to elicit a
neuroinflammatory response14,15. However, no PET study
so far has found a correlation between peripheral and
central inflammatory markers in patients with depression,
and so the mechanism underpinning these co-existing
findings remains unclear4. Moreover, a recent meta-
analysis from our team4 has highlighted the heterogeneity
of these PET studies in terms of study design, methods,
and selected sample. For example, studies using first
generation radiotracers used the binding potential as
endpoint, which is calculated by normalizing the activity
in the target region with the activity of a region devoid of
TSPO; since TSPO is ubiquitous, in this case normal-
ization is achieved by a pseudo-reference region with a
kinetic profile similar to the one measured in healthy
controls16. The quantification of second generation tra-
cers, instead, mostly uses the volume of distribution as
endpoint, which is the estimated ratio at equilibrium
between the activity in the target and the activity in
plasma16.
Of note, there are also quite a lot of differences between
these studies in depression. For example, and of particular
relevance to the present study, only two studies6,11 cor-
rected for the free-plasma fraction of the ligand, that is,
how much of the ligand is available for brain tissue
binding as it is not bound to plasma proteins, which is
important given the evidence of TSPO ligand binding to
peripheral inflammatory proteins17. Moreover, studies
included depressed patients with different ages (including
late-life depression8), symptoms severity, and medication
status18, and only three examined drug-free depressed
patients9–11.
Considering the intrinsic clinical heterogeneity of the
depressed clinical population, studies in healthy volun-
teers are important to dissect the mechanisms linking
peripheral and central inflammation. Experimental mod-
els in animals have demonstrated that microglial activa-
tion can be induced by a peripheral immune challenge; for
example, many studies have used Escherichia coli lipo-
polysaccharide (LPS) as peripheral immune challenge to
elicit microglial activation in rodents19,20. In line with this
evidence, two TSPO-PET studies have investigated non-
human primates following LPS administration, and both
showed a significant increase in TSPO [11C]PBR28 bind-
ing in the brain21,22. Moreover, the study by Hannestad
and colleagues also found correlations between peripheral
cytokines levels and the TSPO binding. So far, only one
PET study (also with [11C]PBR28) has used LPS in
humans, in eight healthy males, finding increased TSPO
binding (by 30–60%) after 3 h from the LPS injection,
although TSPO binding did not correlate with peripheral
inflammation nor with measures of mood23.
In the present study, we examine peripherally induced
systemic inflammation and brain TSPO binding in healthy
humans using interferon (IFN)-α24,25. IFN-α is a pro-
inflammatory cytokine with antiviral, anticancer, and
immunomodulatory effects, approved for treatment of
cancer and chronic hepatitis C26,27. IFN-α induces a sys-
temic immune response associated with sickness beha-
viour, and, when administered over weeks or months as a
treatment for patients with cancer or hepatitis C, is
associated with a diagnosis of major depression in up to
30–50% of patients, and is thus considered the most
validated clinical model of inflammation-induced
depression28. Supporting our choice of using this model,
preclinical studies have shown that peripheral IFN-α
treatment in mice induces activation of microglia, and
that this activation is associated with depressive-like
behaviour29,30.
Similarly to the aforementioned LPS study in humans23,
here we measure microglial activation with [11C]PBR28
PET, before and 24 h after a single IFN-α administration,
in seven healthy male subjects. Of note, second generation
ligands, such as [11C]PBR28, show a higher signal-to-noise
ratio compared with first generation ones, facilitating
measurement of significant within-subjects changes with
a smaller sample size5. However, their binding affinity
depends on the rs6971 nucleotide polymorphism on the
TSPO gene31, and the quantification of the brain signal is
confounded by the presence of abundant TSPO in
endothelial cells and by the high ligand affinity for plasma
proteins32. Here we apply a quantification methodology
that takes into account all these limitations—something
which the previous LPS study did not do. The decision to
have the second PET scan 24 h after the IFN-α adminis-
tration was based on preclinical studies showing that
in vitro IFN-α-stimulated microglia releases inflammatory
cytokines after approximately 24 h29. We also measure the
levels of peripheral cytokines and the transient changes in
mood after IFN-α. Based on the evidence discussed above,
we hypothesize that the IFN-α injection would induce an
increase in brain TSPO binding, in peripheral inflamma-
tion and in depressive-like symptoms, with possible cor-
relations between these three sets of variables.
Materials and methods
Subjects
Seven healthy males provided written informed consent
and participated in the study. This study was approved by
the Queen Square London Ethical committee, ref. 16/LO/
1520. Participants were recruited through King’s College
London internal e-mail, online platforms and public
advertising. In order to determine eligibility, participants
had a pre-screening phone call, followed by a screening
visit. Their medical history was collected, ad a MINI
Psychiatric scale administered. Eligible participants were
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non-smokers, drank no more than five alcohol drinks per
week, had no history of significant medical illness and did
not meet the criteria for any current or past psychiatric or
substance-dependence diagnosis. Subjects were excluded
if they had had an infection in the last month or had
regularly used anti-inflammatory drugs. Subjects were
also instructed to abstain from alcohol, anti-inflammatory
medication and physical exercise for 72 h before the scans.
During the screening visit, participants were genotyped
for the rs6971 polymorphism of the TSPO gene. Only
high-affinity binders (HABs) of [11C]PBR28 were included
(see Table 1 for main sociodemographic features).
Study design
Each participant was assessed four times: at a Screening
Visit, to evaluate their eligibility; at Visit 1, when we
collected the baseline venous blood sample to measure C-
reactive protein (CRP) as a peripheral inflammatory
marker, and participants had their first (baseline) PET
scan; at Visit 2, when IFN-α was administered, and serum
peripheral biomarkers (CRP and cytokines) and clinical
symptoms were measured 1 h before, and at 2, 4, and 6 h
after the injection; and at Visit 3, 24 h after the adminis-
tration of IFN-α, when serum peripheral biomarkers (CRP
and cytokines) and clinical symptoms were again assessed,
and participants had their second PET scan (see Fig. 1 for
a summary of the study design).
The two [11C]PBR28 PET scans lasted 90min each, with
7 or 8 days between the 2 scans for most patients (that is,
Visit 1 and Visit 3), although two participants had the
second scans 1 and 6 months after the first, but always
24 h after the IFN-α injection (that is, Visit 3 was always
24 h after Visit 2) (Fig. 1). To minimise intra and inter-
subject variability, and limiting the effects of circadian
rhythm on TSPO density33,34, all scans were conducted
between 13:00 and 15:30, and within each individual both
scans were conducted at exactly the same time (Table 1,
Supplemental Material). All subjects underwent high-
resolution T1 magnetic resonance imaging (MRI), before
IFN-α administration, in a Siemens Tim Trio 3 T scanner
(Siemens healthcare, Erlangen, Germany); these structural
MRI images were co-registered with the PET imaging to
identify the anatomical regions of interest. All experi-
mental variables related to PET imaging acquisition are
described in Supplemental Materials.
IFN-α administration
At visit 2, participants received a subcutaneous injection
of IFN-α 2a (Roferon-A 3 million IU/0.5 ml solution for
injection). We monitored vital signs (heart rate, blood
pressure, temperature) and the occurrence of adverse
effects every hour for 8 h after the injection. Participants
were allowed to take 1 gr of paracetamol, once or twice, if
sickness symptoms were difficult to tolerate, and six out
of the seven participants did so.
PET imaging
an initial low-dose computer tomography (CT) scan was
acquired for attenuation and scatter correction using
Siemens Biograph™ True Point™ PET/CT scanner (Sie-
mens Medical Systems, Germany). Subjects then received
a bolus injection of [11C]PBR28 (target dose ∼300 Mbq)
followed by a 90-min PET emission scan. PET data were
acquired in 3D mode and binned into 26 frames (dura-
tions: 8 × 15 s, 3 × 1min, 5 × 2min, 5 × 5min, 5 × 10min).
Images were reconstructed using filtered back projection
and corrected for attenuation and scatter. Radio-
pharmaceutical preparation acquisition protocol were
consistent with previous studies35–37.
In parallel to the PET acquisition, arterial blood was
sampled from the radial artery using a combined auto-
matic and manual approach. A continuous sampling
system (ABSS Allogg, Mariefred, Sweden) was used to
measure whole blood activity for the first 15 min of each
Table 1 Sociodemographic data at Screening Visit.
Subject Age (years) Ethnicity BMI (kg/m2)
1 28 Black-African 20.38
2 25 Black-African 23.12
3 33 Asian-Filippino 24.54
4 43 Black-African 24.68
5 29 White-British 23.62
6 26 Black-Carribean 25.62
7 25 Mixed 22.24
Mean ± SD 29.85 ± 6.44 — 23.46 ± 1.75
Screening 
visit
Visit 1 Visit 2 Visit 3
Baseline Day 7 Day 8
-Peripheral
inflammation
-TSPO-PET 
signal
-Clinical
symptoms
-Peripheral
inflammation
-TSPO-PET 
signal
-Clinical
symptoms
-Peripheral
inflammation
-Clinical
symptoms
(1 hour before, 2 
hours after, 4 hours 
after, 6 hours after 
IFN- )
4 time points1 time point 1 time point
(24 hours after IFN- )
Fig. 1 Study design. After a screening visit to assess their eligibility,
participants attended three more visits. TSPO-PET signal was collected at
2 timepoints (before and after the immune challenge); data on
peripheral inflammation and clinical symptoms were collected at 6
timepoints (2 before and 4 after the immune challenge).
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scan at the rate of one sample per second. Discrete blood
samples were manually taken at 5, 10, 15, 20, 25, 30, 40,
50, 60, 70, 80, and 90min, centrifuged and used to
determine the plasma over blood activity ratio (POB).
Samples at 5, 10, and 15min were used to calibrate the
two sampling modalities. Samples taken at 5, 10, 20, 30,
50, 70, and 90 min were also analysed using radio-high
performance liquid chromatography (HPLC) to calculate
the plasma fraction of ligand free of metabolites (PPf).
Radiometabolite analysis of [11C]PBR28 in the blood was
done as described previously35. Ligand free-plasma frac-
tion (fp), or the portion of [11C]PBR28 unbound to plasma
proteins, was determined for all scans using
ultrafiltration-based method as previously described6.
Imaging analysis
Structural MRI images were used for grey/white matter
segmentation and region of interest (ROI) definition. A
neuroanatomical atlas was co-registered on each subject’s
MRI scan and PET image using a combination of Statis-
tical Parametric Mapping 8 (http://www.fil.ion.ucl.ac.uk/
spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) func-
tions, implemented in MIAKAT™ (http://www.imanova.
co.uk). ROIs included occipital lobe, temporal lobe,
frontal lobe, parietal lobe, insular cortex, cingulate cortex,
amygdala, hippocampus, thalamus, striatum, and cere-
bellum. All PET images were corrected for head move-
ment using non-attenuation-corrected images as they
include greater scalp signal, which improves realignment
compared to attenuation-corrected images. Frames were
realigned to a single “reference” space identified by the
PET frame with the highest activity. The transformation
parameters were then applied to the corresponding
attenuation-corrected PET frames to create a movement-
corrected dynamic image for analysis. Regional tissue-
time activity curves (TACs) were obtained by sampling
the image with the co-registered atlas.
Arterial blood data processing
Processing of blood samples was performed consistently
with previous studies35. Both POB and PPf were fitted
with an extended Hill model38 that provided the best data
description39. Whole blood TACs were fitted using a
variation of Feng’s model that consists in a straight line to
the arterial input function peak followed by a tri-
exponential decay40. For each scan, the difference
between ligand arrival time in the brain and arterial
sampling site was estimated by shifting blood curves
0–20 s (both parent and whole blood TACs), fitting the
whole brain TAC (using exponential spectral analysis to
avoid dependency on a particular compartmental model),
and selecting the delay that produced the smallest
weighted residual sum of squares.
Kinetic analysis
Quantification of [11C]PBR28 tissue distribution was
performed using both the standard 2TCM and the
2TCM-1K with total distribution volume (Vt) as main
parameter of interest41. The two models were then used
to assess Vt changes before and after IFN-α (%ΔVt), as
done in a previous study42.
Biomarkers of peripheral inflammation
At Visit 1 (baseline), a blood sample was collected for
the first CRP analysis at the time of the first PET scan. At
Visit 2, blood samples were taken 1 h before IFN-α
injection, and at 2, 4, and 6 h after IFN-α injection, and
then, at Visit 3, at 24 h after IFN-α injection, to measure
CRP and other immune biomarkers, based on previous
work by Cassidy et al.43 (Fig. 1). Serum high sensitivity C-
reactive protein (hsCRP) was assayed on the Siemens
Advia 2400 Chemistry analyser (Siemens Healthcare
Diagnostics, Frimley, UK)44. Serum cytokines were mea-
sured using Meso Scale Discovery (MSD) V-PLEX sand-
wich immunoassays45,46, and plates read on an MSD
QuickPlex SQ 120, as in a previous study conducted in
our laboratory47,48. MSD Pro-inflammatory Panel 1
(human) kit was used for the measurement of IFN-γ, IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and
TNF-α, and a custom Cytokine Panel 1 (human) kit was
used for the measurement of IL-7, IL-17 A and vascular
endothelial growth factor VEGF-A. The inter-assay coef-
ficient of variations was <10%. The results were analysed
using MSD DISCOVERY WORKBENCH analysis soft-
ware. Finally, levels of serum S100B protein were measured
in serum as a marker of blood–brain barrier (BBB) per-
meability49,50, using a S100B kit distributed by Diasorin,
Charles House, Toutley Road, Wokingham, Berkshire, run
on the Liaison XL chemiluminescence analyser51,52.
We measured levels of tryptophan, kynurenine and
kynurenine pathway metabolites, 3-hydroxykynurenine
and kynurenic acid53,54 using automated online solid-
phase extraction HPLC-tandem mass spectrometry (see
Supplemental Material).
Clinical symptoms
The Mini International Neuropsychiatric Interview
(MINI) was used at Screening Visit to diagnose a previous
history of psychiatric disorders55. At all timepoints, from
Visit 1 to Visit 3, the Profile of Mood States (POMS-2)
and the State Anxiety Inventory (STAI-S) were adminis-
tered to assess how participants were feeling “right now”.
These are self-administered tools, which allow to easily
test-retest affect states and sickness symptoms56,57. In
particular, POMS and STAI-S have already been used in
studies assessing behavioural symptoms following IFN-
α58 and LPS injection59.
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Statistical analysis
We performed two-tailed, paired t-tests with p < 0.05 to
investigate differences in [11C]PBR28 signal between
baseline and IFN-α challenge (~24 h after the injection).
Vt values showed a normal distribution in both 2TCM and
2TCM-K1 models, before and after fp correction (all p >
0.5 with the Shapiro-Wilk test). Changes in cytokines and
clinical measures were analysed using repeated measures
ANOVA followed by paired t-test comparing baseline
values (1 h before IFN-α) with those at 2, 4, 6, and 24 h.
Correlation analyses were performed to test the associa-
tion between changes in Vt and changes in cytokines levels
and in clinical symptoms scores. While clinical symptoms
scores were normally distributed, cytokines values were
not, so we applied a logarithmic transformation. All data
are presented as mean and standard errors of the mean.
Results
Measured [11C]PBR28 PET uptake is influenced by
inflammation-induced changes in the free-plasma fraction
of the radioligand, and there are no IFN-α effects once
adjusted for this
The administration of IFN-α led to a generalized
reduction of [11C]PBR28 PET uptake across the entire
brain in all subjects but one (Fig. 2a, lower part). Between
baseline and 24 h after the challenge, the 2TCM model
showed a whole brain mean signal reduction (%ΔVt mean
± SE) of −20 ± 4% (paired t-test t=−4.18, p= 0.01), with
only one participant showing a 2% increase. The other
regions of interest showed a similar pattern of reduction,
ranging from −14% for the Amygdala, to −26% for the
Insular cortex (Fig. 2a, upper part).
Interestingly, 77% of this change in Vt between the two
scans was caused by a change in tracer blood-to-tissue
transport (K1), suggesting a reduced availability of ligand
blood flow to the brain. In order to examine whether this
reduced availability might be related to the ligand binding
to plasma proteins, we further analyzed the ligand free-
plasma fraction (fp) and its effect on the arterial blood and
plasma [11C]PBR28 activity. Indeed, the fp decreased
significantly in the second scan, (%Δfp=−18 ± 16%,
mixed effects modelling z=−2, p= 0.045). Similarly,
arterial whole blood (Cb) and plasma (Cp) [11C]PBR28
radioactivity were significantly affected by IFN-α admin-
istration, compared to baseline conditions, with a pattern
indicating a reduction in the ligand available to bind to
TSPO in the brain. Peak activities and area under the
curve (AUC) for both Cp and Cb TACs significantly
increased in the second scan, with relative differences of
30 ± 13% for peak Cp (paired t-test t6=−2.63, p= 0.04),
25 ± 4% for AUC Cp (paired t-test t6=−5.11, p= 0.002),
14 ± 8% for peak Cb (paired t-test t6=−1.91, p= 0.11),
and 34 ± 6% for AUC Cb (paired t-test t6=−6.23 p=
0.004). Moreover, a positive correlation was found
between the peripheral plasma binding (1-fp) and both
AUC Cp (Pearson’s r= 0.61, p= 0.02) and AUC Cb
(Pearson’s r= 0.64, p= 0.01) (Fig. 2b). These associations
were consistent with increased retention of the ligand in
plasma to the increased peripheral inflammatory proteins
induced by IFN-α.
Considering the increased plasma binding of the ligand
resulting from arterial blood analyses, we corrected results
for fp. Interestingly, after this correction, Vt paired t-test
between the 2 scans dramatically changed and was no
longer significant, with four subjects showing an increase
in Vt (ranging from 3 to 198%) and three subjects showing
a decrease (ranging from −52 to −9%) (Fig. 2c, lower part),
averaging 23 ± 31% (t= 0.1, p= 0.91). Similar results were
present when analyzing specific ROIs (Fig. 2c, upper part).
Results did not change after we repeated all the analyses
using the endothelial model 2TCM-1K, again showing a
significant decrease using the unadjusted mean whole
brain %ΔVt (−28 ± 19%, t=−3.06, p= 0.02) and no dif-
ferences in %ΔVt after fp correction (7 ± 54%, t= 0.59,
p= 0.57) (Fig. 2a–c).
IFN-α increases peripheral biomarkers of inflammation
IFN-α administration resulted in significant changes in
serum biomarkers at 4–24 h after the challenge. Com-
pared with 1 h before IFN-α, repeated measures ANOVA
was significant for hsCRP (F1.2,7.1= 44.3, p < 0.001), IL-6
(F4,24= 29.70, p < 0.001), IL-7 (F4,24= 6.49, p= 0.001),
IL-8 (F2.5,15.3= 9.11, p < 0.001), IL-10 (F1.3,7.9= 64.62, p <
0.001), IFN-γ (F1.6,10.0= 32.27, p < 0.001), TNF-α (F4,24=
21.10, p < 0.001), and VEGF-A (F4,24= 7.71, p < 0.001),
with significant increases (using LSD pairways compar-
isons) at both 4 and 6 h for all biomarkers, except hsCRP
and IL-8 which increased at 24 h only, IL-7 which
increased at 6 h only, and VEGF-A which decreased at
24 h (Fig. 3). Of note is also that TNF-α was still increased
at 24 h. Kynurenine/Tryptophan (K/T) ratio also showed
an increase at 24 h, but this did not reach statistical sig-
nificance (86 ± 59.5 folds, F4,20= 1.94, p= 0.1) (Fig. 3).
S100B protein did not change significantly (change at
24 h: 35 ± 60%, F1.1,6.7= 3.4, p= 0.1).
Values of hsCRP measured at the time of the baseline
and post-interferon PET scan correlated with the ligand
protein binding (1-fp) (Pearson’s r= 0.57, p= 0.03) and
were inversely associated with K1 values estimates
(Pearson’s r=−0.75, p= 0.002), indicating that higher
peripheral inflammation was associated with increased
binding of the ligand to plasma protein and decreased
availability of the ligand for entry into the brain.
IFN-α induces transient mood changes and sickness
symptoms
We found increased sickness symptoms at 4–6 h after
the challenge (Fig. 4), as shown by an increase in POMS-2
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Fig. 2 IFN-α administration effect on [11C]PBR28 binding (Vt) from baseline in healthy control subjects (n= 7). Results before (a) and after (c)
fp correction are shown as regional percent increase in Vt (ΔVt) averaged across subjects (top images error bars are SEM) and Vt change for each
subject averaged across regions (bottom images). IFN-α administration decreased [11C]PBR28 Vt across the brain, but after correction for radioligand
free-plasma fraction there were no longer any changes. b Peak activities and area under the curve (AUC) for both plasma (Cp) and whole blood (Cb)
showed a significant increase in the second scan and positively correlated with plasma protein binding.
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Total Mood Disturbance (TMD) (F4,24= 4.6, p= 0.006),
POMS-2 Confusion-bewilderment (F4,24= 3.12, p= 0.03)
and POMS-2 Fatigue-Inertia (F1.2,7.2= 7.71, p= 0.02) at
6 h, and a reduction in POMS-2 Vigor-Activity (F4,24=
5.86, p= 0.02) and POMS-2 Friendliness (F4,24= 3.80,
p= 0.02) at 4 h. Finally, the STAI-S scores peaked at 4 h
after IFN-α (F4,24= 2.94, p= 0.04). Delta hsCRP (at 24 h)
was positively correlated with delta POMS TMD score (at
6 h) (Pearson’s r= 0.88, p= 0.009).
IFN-α increases body temperature, blood pressure, and
heart rate
Vital signs were closely monitored after IFN-α admin-
istration. From 1 h before the injection to 8 h after, we
detected significant increases in body temperature
(+1.1 °C, from 36,3 °C to 37,4 °C, t=−6.10, p= 0.001)
and heart rate (+24 bpm, from 65 bpm to 89 bpm, t=
−3.1, p= 0.02). Average but not statistically significant
increases were found also in systolic blood pressure
(+16 mmHg, from 123mmHg to 139mmHg) and dia-
stolic blood pressure (+3mmHg, from 63mmHg to
66mmHg).
Discussion
Here we investigate the association between peripheral
and central inflammation in healthy humans, using the
immune challenge IFN-α. We show that IFN-α induces
peripheral inflammation that is comparable, and some-
times more intense, than that described in depression, in
association with acute mood changes. However, we can-
not measure a neuroinflammatory response with TSPO-
PET imaging. Our thorough methodology addresses all
limitations affecting second generation high-affinity tra-
cers: we only select high-affinity binders (HABs); we use
both 2TCM and 2TCMK1 models to correct for endo-
thelial binding; and we normalize results for fp, that is, for
the amount of ligand that is able to enter the brain
because it is free from binding to plasma proteins.
Overall, this study confirms that brain TSPO binding is
strongly affected by the free-plasma fraction artefact32.
The evidence that Vt changes are mainly explained by
blood flow (K1) changes, and that the initial Vt decrease
disappears after fp correction, indicates that the signal
differences between the two PET scans are mainly driven
by changes in the availability of free ligand in the plasma
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after the immune challenge. This is further supported by
the positive correlation between inflammation (hsCRP
levels) and ligand protein binding, and the negative cor-
relation between hsCRP levels and K1. Our data thus
support the notion that peripheral inflammation, here
occurring with the IFN-α injection, induces an increase in
the ligand’s peripheral plasma binding and thus results in
a lower proportion of ligand available for TSPO binding in
the brain. This important methodological limitation sug-
gests that the pathophysiological implications of altered
brain TSPO-PET signal are difficult to interpret, thus
limiting its usefulness as a sensitive marker of neuroin-
flammation and microglial activation. Of course, our
findings are in apparent contrast with the aforementioned
studies, which found increased brain TSPO-PET signal in
healthy humans after LPS injection, or in patients with
depression, a condition associated with increased
inflammation. However, many mechanisms can explain
this potential discrepancy.
In the aforementioned study23, LPS administration in
eight healthy males induced much stronger and faster
peripheral pro-inflammatory responses compared with
IFN-α in our study, partly because LPS acts immediately
on toll-like receptors that directly activate the NK-FB
pathway14. IFN-α, instead, acts through several inter-
mediate steps, including the Jack/STAT/ISGF3 pathway60,
with the NK-FB pathway as an alternative route of
action61. For example, IL-6 levels were ~100 pg/ml at 4 h
in the LPS study (having reached an average of 200 pg/ml
at previous timepoints), while IL-6 levels average around
6 pg/ml at 4 h in our study. Consistent with this, the LPS
in that study induced much stronger physiological
responses compared with IFN-α in our study, that is,
twice the increase in body temperature, and ~+50% in the
increase in heart rate. Moreover, these changes happened
already at 3 h from the challenge, showing a quicker
mechanism of action compared with IFN-α. Finally, and
most relevant for the potential discrepancy with our
findings, the LPS study did not apply the fp correction, so
we have no information on the relationship between acute
LPS-induced inflammation, free ligand in the plasma, and
brain TSPO signal. Incidentally, this same limitation also
applies to the two studies using LPS in non-human
primates21,22.
The second finding in apparent contrast with our results
is the presence of increased TSPO binding in patients
with depression, as shown by some of the studies con-
ducted so far. However, it is of note that the two studies
which used [11C]PBR28 and corrected for fp effect, like
we do, found no difference6, or a borderline-significant
increase, in TSPO-PET signal11. The other studies that
found increased TSPO-PET signal7–10,18 used different,
first and second generation radioligands, and did not
correct for fp, and so they did not take into consideration
the ligand binding to plasma proteins. Moreover, of the
studies reporting an increased TSPO-PET signal, only two
examined depressed patients with increased inflamma-
tion8,10, and TSPO-PET signal in depressed patients did
not correlate with peripheral inflammation.
It is interesting to note that the levels of peripheral
inflammation in our study do indeed resemble those
present in patients with major depression. For example,
the Hedges effect size of IL-6 and TNF-α differences from
baseline to 24 h after IFN-α are 0.48 and 0.66, respectively,
which are very close to the difference between controls
and patients with depression for these two cytokines, as
shown by Hedges g= 0.62 and 0.68, respectively62. Values
of hsCRP at 24 h are higher in our study compared with
average depressed patients’ values, as we obtain a mean of
around 10mg/L and Hedges’ g= 1.69 compared with
baseline, vs values in most depressed patients between 1
and 3mg/L13 and Cohen’s d= 0.47 for the difference
between controls and depressed patients63. However,
values reached in our study still have clinical relevance for
mental health, as one previous study has found that CRP
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levels above 10mg/L are associated with a high risk of
developing future depression64. Thus, the immune chal-
lenge with acute IFN-α can be used to examine the neural
and immunological regulatory response to an immune
perturbation that is within the same magnitude of that
described in depression, as opposed to, for example, the
much more intense activation of inflammatory processes
induced by LPS in the aforementioned study23. Further
discussion of our immune findings, including the reduc-
tion of VEGF-A, is in the Supplementary Material.
Of course, brain TSPO-PET signal is markedly upre-
gulated in clinical conditions that have neuroinflamma-
tion at their core, such as Huntington’s disease or multiple
sclerosis. Indeed, positive correlations between levels of
pro-inflammatory cytokines and brain TSPO-PET signal
have been found in neurological conditions associated
with genuine neuroinflammatory processes65, but not in
studies of psychiatric patients66,67. Thus, beyond the dif-
ferent technical approaches in the analyses of the PET
data, the variability in the results of TSPO-PET studies in
psychiatric patients (or in studies that, as ours, mimic the
levels of peripheral inflammation described in psychiatric
patients), may simply reflect a true lack of microglial
activation. Indeed, Notter and colleagues67 have recently
highlighted that the brain expression of inflammation-
related genes, the microglial phenotypes, the presence of
reactive gliosis, and the levels of cerebrospinal fluid (CSF)
cytokines, are all very different in true neuroimmunolo-
gical disorders, such as multiple sclerosis, compared with
psychiatric disorders. Thus, PET radiotracers targeting
alternative markers of immune response might be needed
to capture inflammatory processes in the brains of
patients with psychiatric disorders68, together with CSF
analyses, as recently done by Felger and colleagues69 and
other studies in depressed patients4. Moreover, TSPO
signal can be driven by factors other than microglial
activation70, such as recruitment of peripheral monocytes
into the parenchyma, adherence of circulating leucocytes
to the vascular endothelium, and the expression of TSPO
in various brain cells, including microglia, astrocytes,
vascular endothelial cells and neurons. Unfortunately, the
lack of cellular specificity is often neglected when inter-
preting PET studies, as well the potential changes in
blood–brain barrier permeability and the need to correct
for the endothelial component of TSPO signal (as we do
in our study). Nevertheless, as our challenge is acute, we
cannot exclude the possibility that some depressed
patients do have increased brain TSPO-PET signal
because of microglial activation, as a consequence of
increased inflammation lasting months or even years
before the study, rather than just 24 h. In fact, long-lasting
inflammation in depression may be driven either by early
risk factors, such as childhood maltreatment or antenatal
depression71–73, or present during previous relapses or
exacerbations, even if not measurable on the day of
the scan.
This study has some limitations. First, it is possible that
the timing of the second PET scan might not have been
ideal to detect neuroinflammation. Although we had
based our decision to do the second scan at 24 h on
preclinical studies29, we find that significant sickness
symptoms were present at around 4–6 h after the chal-
lenge, together with the peak in IL-6, IL-10, and IFN-γ, so
we cannot exclude that an increased brain TSPO binding
could have been measured at that timepoint. It is also
possible that a regulatory anti-inflammatory response
could have started at 24 h, and this could have con-
founded the results. However, some other inflammatory
markers relevant to depression were either increased only
at 24 h (hsCRP, IL-8) or increased at all timepoints,
including 24 h (TNF-α), indicating that systemic inflam-
matory processes were still present at the time of the
second scan. Our research was also limited by the small
sample size. However, PET studies are extremely invasive,
challenging and expensive, and studies with two repeated
PET scans at such a short distance tend to have numbers
in the range of 6–8 subjects, like in the aforementioned
study in healthy humans with LPS, which had eight
subjects23.
Conclusion
To our knowledge, this is the first study assessing cen-
tral inflammatory responses to IFN-α in healthy humans
by using PET together with an assessment of peripheral
inflammatory biomarkers. While the ability of IFN-α to
induce acute inflammatory responses and mood changes
highlights its potential as an immune model of depression
for future studies in healthy humans, we find no evidence
of a putative neuroinflammatory response, and we
unequivocally demonstrate that brain TSPO-PET signal
measurement is confounded by the inflammation-induced
changes in [11C]PBR28 free ligand in the plasma. In
conclusion, there is an urgent call for new targets of
microglial activation that could also better clarify the role
of TSPO in measuring neuroinflammation, especially if
coupled with CSF analysis.
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